UK’s NICE reverses decision on uveal melanoma therapy
Immunocore Holdings’ Kimmtrak (tebentafusp) has been recommended for funding through the National Health Service (NHS) in England by the National Institute for Health and Care Excellence (NICE). NICE has recommended KIMMTRAK within its marketing authorisation for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. … Read More